Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.02 HKD | +1.01% | +5.88% | -3.31% |
02:25pm | CSPC Pharmaceutical Trustee Repurchases Further Shares Under Award Scheme | MT |
Jun. 06 | Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.31% | 10.54B | B | ||
+46.04% | 754B | C+ | ||
+41.24% | 630B | B | ||
-5.84% | 352B | C+ | ||
+20.23% | 331B | B- | ||
+9.43% | 298B | C+ | ||
+18.87% | 250B | B+ | ||
+12.16% | 217B | B- | ||
-0.65% | 216B | A+ | ||
+6.59% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1093 Stock
- Ratings CSPC Pharmaceutical Group Ltd.